Stephen Tsang, MD, Ophthalmology, New York, NY, New York-Presbyterian Hospital

StephenHing-LamTsangMDPhD

Ophthalmology New York, NY

Retinal Disease, Uveitis

Professor of Ophthalmology, Pathology & Cell Biology (tenured), Columbia Stem Cell Initiative

Dr. Tsang is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tsang's full profile

Already have an account?

Summary

  • Dr. Tsang successfully treated preclinical models of Pde6a, Pde6b, Mfrp, Rho, Cngb1 and autosomal recessive bestrophin retinopathies. He has expertise in designing and testing genome engineering strategies in pre-clinical models, developing patient-specific knock-in models, generating of patient cell lines and providing care to patients with a precision medicine approach. PI is also leading efforts in FDA trials for retinal degenerations, including PDE6A, RAB geranylgeranyl transferase, RPGR, CNGB3, CNGA3 and ABCA4 retinopathies. Since 1992, PI has been culturing embryonic stem (ES) cells, and, in 1995, created the first mouse model for a recessive form of Retinitis Pigmentosa.

    K08EY000408 and MSTP # T32 GM 073667 had allowed the PI to become one of a handful of clinicians to direct the full spectrum of bench-to-bedside research. PI’s research on cGMP-phosphodiesterase (PDE6) is a case in point. PDE6 defects lead to blindness in 72,000 people worldwide. PI generated the world’s first gene-targeted model of retinitis pigmentosa (a PDE6 mutant), and then used these mice to dissect the underlying pathophysiology. These studies led to novel and fundamental discoveries on PDE6 regulation of G-protein-coupled-receptor signaling and, eventually, preclinical testing in the same mice; of the different therapies tested, viral-gene therapy is slated for clinical trials.
    PI has extensive experience in creating patient-specific induced pluripotent stem cell (iPSC) and related iPS-RPE cell lines as disease models for retinal diseases. PI created patient-specific iPSC and iPSC-RPE lines and used them as a disease model in the preclinical study of gene therapy for Membrane Frizzled-related Protein (MFRP), an autosomal recessive retinitis pigmentosa (RP). (Li Y, ……, TSANG, S.H. Gene therapy in patient-specific stem cell lines and a preclinical model of retinitis pigmentosa with membrane frizzled-related protein (MFRP) defects. (2014) Molecular Therapy. 2014 Sep;22(9):1688-97).
  • A metabolic approach for retinal degeneration

    Retinitis pigmentosa (RP) is a heterogeneous genetic disorder that is characterized by a progressive loss of photoreceptors that results in deterioration of vis

    Using CRISPR to Treat Blindness

    PI and Professor Vinit Mahajan have used a new gene-editing technology called CRISPR, to repair a genetic mutation respons

    Addressing the point of no return for gene therapy

    Retinitis pigmentosa (RP) is hereditary retinal degenerative disease that is characterized by progressive loss of photoreceptor function. In human trials, gene

    The First Retinal Gene Therapy Trial @ Moorfields

    Among the many hoped-for benefits of the revolutionary gene-editing technology CRISPR is treating, or even curing, diseases. At the 2016 World Science Festival,

Education & Training

  • UCLA Medical Center
    UCLA Medical CenterResidency, Ophthalmology, 1999 - 2003
  • UCLA Medical Center J Stein Eye Institute
    UCLA Medical Center J Stein Eye InstituteResidency, Ophthalmology, 1999 - 2003
  • Columbia University College of Physicians & Surgeons
    Columbia University College of Physicians & SurgeonsClass of 1998
  • Columbia University
    Columbia UniversityPh.D., Integrated Program, 1996
  • Columbia University
    Columbia UniversityM.Phil., Mammalian Genetics, 1993
  • Johns Hopkins University
    Johns Hopkins UniversityA.B., Biology, Departmental Honors, 1986 - 1989

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2001 - Present
  • NY State Medical License
    NY State Medical License 1999 - 2022
  • American Board of Ophthalmology Ophthalmology
  • American Ophthalmological SocietyMember
  • Macular SocietyMember

Awards, Honors, & Recognition

  • Young Investigator Award Macular Society, 2018
  • Elected, American Society of Clinical Investigation 2016
  • American Ophthalmlological Society member, 2015
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Presumed Chloroquine Retinopathy with Short-Term Therapy for Glioblastoma Multiforme  
    Stephen Tsang, MD, JAMA Ophthalmology
  • Quantitative Autofluorescence Following Gene Therapy with Voretigene Neparvovec  
    Stephen Tsang, MD, JAMA Ophthalmology
  • Stargardt Juvenile Macular Degeneration  
    Stephen Tsang, MD, New England Journal of Medicine
  • Join now to see all

Authored Content

  • Quantitative Autofluorescence Following Gene Therapy with Voretigene NeparvovecJune 2020
  • Stargardt Juvenile Macular DegenerationJune 2020

Grant Support

  • Gene Silencing and Gene Editing in PhototransductionNIH2019
  • Defining Barriers to Gene TherapyNIH2018
  • Comparative Effectiveness of Embryonic and Induced Pluripotent Stem Cell-Based TherapiesNew York State2017

Other Languages

  • Chinese (Cantonese)

Hospital Affiliations